It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany)
to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod.
The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH’ was presented at DDW 2021, May 21-23.
- Could you give us a brief overview of the True North study and its findings? (0:11)
- Why is corticosteroid-free remission an important treatment goal in ulcerative colitis? (1:40)
- How were corticosteroid doses tapered in the maintenance phase of the True North study? (2:25)
- What were the results of the maintenance phase in terms of corticosteroid-free remission? (3:07)
- What are the implications of this finding, both for clinical practice and for future clinical trial design? (3:34)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!